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Abbreviations
IMIDIA Innovative Medicines Initiative for
Diabetes: improving beta-cell function
and identification of diagnostic
biomarkers for treatment
monitoring in diabetes
INNODIA Translational approaches to disease
modifying therapy of type 1 diabetes:
An innovative approach towards
understanding and arresting Type 1 diabetes
LCM Laser capture microdissection
RHAPSODY Assessing risk and progression of
prediabetes and type 2 diabetes to
enable disease modification
T2DSystems Development of a systems
biomedicine approach for risk
identification, prevention and
treatment of type 2 diabetes
To the Editor: We read with much interest the review article by
Hart and Powers, recently published in Diabetologia, on the
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number of projects on islet pathophysiology have been funded
by the European Union, also, in some cases, with the support of
the European Federation of Pharmaceutical Industries and
Associations (EFPIA), JDRF and charitable trusts (such as the
Leona M. and Harry B. Helmsley Charitable Trust). These pro-
jects are IMIDIA (Innovative Medicines Initiative for Diabetes:
improving beta-cell function and identification of diagnostic bio-
markers for treatment monitoring in diabetes, www.imidia.org),
T2DSystems (Development of a systems biomedicine approach
for risk identification, prevention and treatment of type 2
diabetes, www.t2dsystems.eu), RHAPSODY (Assessing risk
and progression of prediabetes and type 2 diabetes to enable
disease modification, www.imi-rhapsody.eu) and INNODIA
(Translational approaches to disease modifying therapy of type
1 diabetes: An innovative approach towards understanding and
arresting Type 1 diabetes, www.innodia.eu). The key
participating islet isolating centres have been scrupulously
preparing and characterising their human islet preparations
(currently more than 400) according to rigorous standardised
procedures. The information to be reported on the donors’
clinical characteristics and isolated islet features will be further
implemented to comply with the emerging requirements [1, 13].
Importantly, the biorepositories of isolated islets generated in
these projects include several well-characterised samples obtain-
ed from organ donors with type 2 diabetes, and these are being
used to shed further light on the pathophysiology of islet cells in
diabetes.
As reported by Hart and Powers [1], the vast majority of
studies on human islet cells have employed islets isolated from
the pancreas of organ donors. The advantages of this model
include the use of transplantation-grade procedures to yield large
amounts of islets that can be evaluated in terms of composition,
function, survival and molecular properties under different ex-
perimental conditions. IMIDIA and RHAPSODY, on the other
hand, also introduced the standardised collection and analysis of
islet samples obtained following pancreatic surgery from non-
diabetic people, individuals with varying degrees of glucose
intolerance, and people with recent-onset diabetes or long-
Table 1 Differences in key fea-
tures of islets isolated from type 2
diabetic vs non-diabetic organ
donors
Feature T2D vs ND islets Reference
Beta cell identity Increased number of de-differentiated beta cells, which correlates
with the reduction of glucose-stimulated insulin release
[4]
Insulin secretory function Reduced insulin release in response to acute glucose challenge,
associated with lower glucose oxidation
Reduced insulin granule exocytosis associated with T2D gene
variants
[5, 6]
Beta cell turnover Increased apoptosis, endoplasmic reticulum stress and islet
cell inflammation
[7]
Possible beta cell rescue Improved insulin secretion from T2D islets after culture [8]
Epigenetics Dysregulation of DNA methylation [9, 10]
Gene expression Different transcriptome signatures [11, 12]
ND, non-diabetic; T2D, type 2 diabetic
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progress and challenges of the use of human islets in the under-
standing of islet cell biology and diabetes [1]. In the initial sec-
tions of the article, the authors highlight the advances in several
areas of human islet cell biology, made possible by the increased
availability of islets for research purposes, isolated from the
pancreases of organ donors [2, 3]. Such areas include islet archi-
tecture, beta cell function and turnover, molecular phenotypes
and comparisons with rodent islets. These sections mainly focus
on islets from non-diabetic donors, and pay limited attention, if
any, to the progress achieved by the use of isolated islets obtained
from diabetic individuals. In fact, over the past 10–15 years,
several studies have contributed to the identification of islet
changes associated with type 1 and, in particular, type 2 diabetes.
Although space limitations do not allow a comprehensive listing
of all the major advances in this field, we think it is important to
summarise at least some key achievements and important differ-
ences between ‘type 2 diabetic’ and ‘non-diabetic’ islets
(Table 1). They comprise islet morphology and ultrastructure,
changes in beta cell identity, insulin secretion defects in response
to selective secretagogues (particularly glucose), possible beta
cell rescue, mechanisms of islet cell death, the role of genetic
and epigenetic factors, gene and protein expression patterns and
the search for biomarkers of sick beta cells [4–12]. Taking into
consideration the differences between healthy and diseased islet
cells is key to elucidating the trajectory of beta cell failure during
early glucose intolerance, diabetes onset and disease progression,
in order to eventually conceive targeted strategies for the preven-
tion, better treatment and possible remission of this disease.
In the second part of their review, Hart and Powers underline
how the characteristics of the islets used in a large proportion of
the available studies are inconsistently and marginally reported,
making comparisons among studies difficult and scarcely reliable
[1]. Hence, the authors propose a list of actions to be put in place,
including a record of standardised information on the islets stud-
ied, to guarantee more sound and reproducible results. We en-
dorse this request and, certainly, the ongoing discussion will help
us to move towards a balance between the need for characterisa-
tion and the feasibility of this [13]. Over the past few years, a
standing type 2 diabetes [4]. This has allowed the study of the
molecular features of islet cells yielded by laser capture micro-
dissection (LCM) [3, 12], as well as morphometric analysis and
study of islet function in fresh tissue slices [14]. One obvious
advantage of this approach is that individuals can be metaboli-
cally investigated before surgery and, if required, after recovery
from the operation. In RHAPSODY, the reliability of this ap-
proach has been corroborated by comparing the transcriptome of
LCM islets from two cohorts of surgical patients collected at
different research sites and according to the same stringent pro-
tocols [15] and through the identification of the largest subset of
islet expression quantitative trait loci (QTLs) to date [16].
Standardisation of the use of this model in different centres will
further contribute to the advancement of human islet research.
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